StreetInsider.com News Articles

CNS Pharmaceuticals outlines oncology and neurology pipeline strategy

Tue, 01 Sep 2026 09:02:30 -0400

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that its Chief Business Officer, Dylan Wenke, participated in a Virtual Investor "What This Means" segment, providing an update on the company's business development strategy.

Wenke outlined the company's approach to evaluating in-licensing and acquisition targets, citing scientific, clinical, regulatory, and commercial criteria as key factors in the evaluation process. The segment covers the company's pipeline focus on oncology and neurology, as well as its sourcing and due diligence process.

The Houston-based biotechnology company is in a period of strategic transformation as it works to build a pipeline in those two therapeutic areas. The press release

CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth

Tue, 01 Sep 2026 09:01:00 -0400

Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" Segment

Access the segment here

HOUSTON, TX / ACCESS Newswire / September 1, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment.

Dylan Wenke, Chief Business Officer of CNS Pharmaceuticals, provided an update on its business development strategy as part of its broader transformation as the Company works

CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth

Tue, 01 Sep 2026 09:01:00 -0400

Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" Segment

Access the segment here

Dylan Wenke, Chief Business Officer of CNS Pharmaceuticals, provided an update on its business development strategy as part of its broader transformation as the Company works

CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference

Thu, 27 Aug 2026 09:01:00 -0400

Video webcast now available here

HOUSTON, TX / ACCESS Newswire / August 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in the Virtual Investor "Why Now" on-demand conference.

Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's strategic transformation that is being built on the strength of its newly assembled executive leadership team, enhanced financial position following its recent financing, and

CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference

Thu, 27 Aug 2026 09:01:00 -0400

Video webcast now available here

Form DEFA14A CNS Pharmaceuticals,

Tue, 25 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260825/26975782.html

Form DEFA14A CNS Pharmaceuticals,

Tue, 25 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260825/26975782.html

Form DEF 14A CNS Pharmaceuticals, For: Sep 30

Fri, 21 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260821/26962457.html

Form DEF 14A CNS Pharmaceuticals, For: Sep 30

Fri, 21 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260821/26962457.html

Form 4 CNS Pharmaceuticals, For: May 18 Filed by: Fisher Michal

Tue, 18 Aug 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260818/26941639.html

Form 4 CNS Pharmaceuticals, For: May 18 Filed by: Fisher Michal

Tue, 18 Aug 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260818/26941639.html

Form 3 CNS Pharmaceuticals, For: May 04 Filed by: Fisher Michal

Tue, 18 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260818/26941532.html

Form 3 CNS Pharmaceuticals, For: May 04 Filed by: Fisher Michal

Tue, 18 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260818/26941532.html

Form 4 CNS Pharmaceuticals, For: Aug 14 Filed by: Levin Rami

Tue, 18 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260818/26941536.html

Form 4 CNS Pharmaceuticals, For: Aug 14 Filed by: Levin Rami

Tue, 18 Aug 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260818/26941536.html

Form SCHEDULE 13G/A CNS Pharmaceuticals, Filed by: Ikarian Capital, LLC

Fri, 14 Aug 2026 21:26:00 -0400

si-local-file:///var/storage/secattach/20260814/26933312.html

Form SCHEDULE 13G/A CNS Pharmaceuticals, Filed by: Ikarian Capital, LLC

Fri, 14 Aug 2026 21:26:00 -0400

si-local-file:///var/storage/secattach/20260814/26933312.html

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation

Wed, 12 Aug 2026 08:00:00 -0400

Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline

HOUSTON, TX / ACCESS Newswire / August 12, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2026 and provided an update on the corporate strategy the company introduced in March 2026.

"We are moving with speed and discipline

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation

Wed, 12 Aug 2026 08:00:00 -0400

"We are moving with speed and discipline

Form 10-Q CNS Pharmaceuticals, For: Jun 30

Wed, 12 Aug 2026 07:56:00 -0400

si-local-file:///var/storage/secattach/20260812/26909049.html

Form 10-Q CNS Pharmaceuticals, For: Jun 30

Wed, 12 Aug 2026 07:56:00 -0400

si-local-file:///var/storage/secattach/20260812/26909049.html

Form 8-K CNS Pharmaceuticals, For: Jul 02

Thu, 02 Jul 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260702/26724046.html

Form 8-K CNS Pharmaceuticals, For: Jul 02

Thu, 02 Jul 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260702/26724046.html

CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment

Mon, 08 Jun 2026 09:15:00 -0400

Access the segment here

HOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment.

Steve O'Loughlin, Chief Financial Officer of CNS Pharmaceuticals, discussed the Company's recently completed oversubscribed $22.5 million financing in the virtual segment, addressing the factors that enabled the successful capital raise following its strategic reset and acquisition-focused

CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment

Mon, 08 Jun 2026 09:15:00 -0400

Access the segment here